Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹964.20
5.00 (0.52%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹15.36K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
38.8
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹786.05+22.7%
52W High₹1,248-22.7%
Current Price
₹964.20
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹771.36
Upper Circuit₹1,157.04
Reference Price
₹964.20
Investment Checklist
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹903.5
Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹949.8
Volume divergence: Bearish (price up, volume down)
Trend: Price below most MAs — downtrend
EMA(50) Crossover: Price crossed below EMA(50): Fresh bearish weakness signal.
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
80%
Trend
BEARISH
BEARISH
Price below most MAs — downtrend
EMA20
971.83
EMA50
964.7
EMA200
1004.42
Price Action
CONSOLIDATION
NEUTRAL
Higher Highs3
Higher Lows5
Lower Highs6
Lower Lows4
Support & Resistance Levels
Resistance (Above)
₹1020.97
₹1102.17
₹1144.67
₹1162.00
₹1183.90
Support (Below)
₹952.22
₹926.90
₹913.70
₹886.30
₹847.20
Volume Analysis
TrendSTABLE
Change-8.20%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Stop Loss Levels
Fixed Risk
1% Risk₹954.56
3% Risk₹935.27
5% Risk₹915.99
7% Risk (Custom)
₹896.71Technical Levels
1x ATR (Volatility)₹937.70
2x ATR (Swing)₹911.20
3x ATR (Trend)₹884.70
Immediate Support₹952.22
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹1,813.7 Cr | ₹1,915.8 Cr | ₹1,878.9 Cr | ₹2,116.1 Cr |
| Net Profit | ₹100.9 Cr | ₹153.6 Cr | ₹102.9 Cr | ₹55.9 Cr |
| EPS | ₹6.37 | — | ₹6.49 | ₹3.52 |
| Operating Profit | ₹277.4 Cr | ₹334.5 Cr | ₹301.5 Cr | ₹270.2 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Jubilant Pharmova Limited | ₹964.20 | -0.52% | 38.8 | ₹15.36K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 25 Jul 2025 | Dividend - Rs 5 Per Share | DIVIDEND |
| 02 Aug 2024 | Dividend - Rs 5 Per Share | DIVIDEND |
| 10 Aug 2023 | Dividend - Rs 5 Per Share | DIVIDEND |
| 11 Aug 2022 | Dividend - Rs 5 Per Share | DIVIDEND |
| 05 Aug 2021 | Dividend - Rs 5 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for JUBLPHARMA
View All
positive
CNBC TV18 - Markets 15d ago
Jubilant Pharmova arm gets tentative USFDA approval for Pantoprazole Oral Suspension
Jubilant Pharmova subsidiary Jubilant Generics gets USFDA tentative nod for Pantoprazole Sodium Oral Suspension, final approval after patent expiry in Dec 2026, shares down over 10% in 6 months
JUBLPHARMAHealthcare
NEWS
positive
Business Standard - Markets 15d ago
Jubilant Pharmova arm gets tentative nod for Pantoprazole oral suspension
Jubilant Pharmova announced that its subsidiary, Jubilant Generics has received a tentative approval from the USFDA US Food and Drug Administration (USFDA) for Pantoprazole Sodium delayed release oral suspension, 40 mg per packet.
JUBLPHARMAHealthcare
NEWS
positive
Business Standard - Markets 16d ago
Stock Alert: Infosys, Vedanta, LIC, Embassy Developments, Jubilant Pharmova
Vedanta incorporated a wholly owned subsidiary, Vedanta Property Platforms (VPPL) in Mumbai, Maharashtra, to undertake real estate business and ancillary activities.
ABRELEMBDLINFYJUBLPHARMATRELVEDLForest MaterialsHealthcare